Relay Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Relay Therapeutics, Inc. (RLAY) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 27.46 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 27.46M shares, a 9.45% increase year-over-year.
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 28.17M shares, a 7.83% increase year-over-year.
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 24.08M shares, a 0.53% increase year-over-year.
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 25.09M shares, a 1.76% decline year-over-year.
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 22.43M shares, a 0.21% increase from fiscal 2024.
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 22.38M shares, a 8.95% increase from fiscal 2023.
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 20.54M shares, a 60.26% increase from fiscal 2022.
- Relay Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 12.82M shares, a 36.22% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 27.46M shares 10-Q · filed 2026-08-06 | 27.46M shares 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | 28.17M shares 10-Q · filed 2026-05-05 | ||||||
| 2025-12-31 | 22.43M shares 10-K · filed 2026-02-26 | ||||||
| 2025-09-30 | 24.08M shares 10-Q · filed 2025-11-06 | 24.08M shares 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | 25.09M shares 10-Q · filed 2026-08-06 | 25.09M shares 10-Q · filed 2026-08-06 | |||||
| 2025-03-31 | 26.13M shares 10-Q · filed 2026-05-05 | ||||||
| 2024-12-31 | 22.38M shares 10-K · filed 2026-02-26 | ||||||
| 2024-09-30 | 23.95M shares 10-Q · filed 2025-11-06 | 23.95M shares 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | 25.54M shares 10-Q · filed 2025-08-07 | 25.54M shares 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | 25.95M shares 10-Q · filed 2025-05-05 | ||||||
| 2023-12-31 | 20.54M shares 10-K · filed 2026-02-26 | ||||||
| 2023-09-30 | 19.49M shares 10-Q · filed 2024-11-06 | 19.49M shares 10-Q · filed 2024-11-06 | |||||
| 2023-06-30 | 19.82M shares 10-Q · filed 2024-08-06 | 19.82M shares 10-Q · filed 2024-08-06 | |||||
| 2023-03-31 | 19.09M shares 10-Q · filed 2024-05-02 | ||||||
| 2022-12-31 | 12.82M shares 10-K · filed 2025-02-26 | 12.62M shares 10-K · filed 2023-02-23 | |||||
| 2022-09-30 | 12.81M shares 10-Q · filed 2023-11-02 | 12.81M shares 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | 13.21M shares 10-Q · filed 2023-08-08 | 13.21M shares 10-Q · filed 2023-08-08 | |||||
| 2022-03-31 | 13.00M shares 10-Q · filed 2023-05-04 | ||||||
| 2021-12-31 | 9.41M shares 10-K · filed 2024-02-22 | ||||||
| 2021-09-30 | 9.54M shares 10-Q · filed 2022-11-03 | 9.54M shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 9.41M shares 10-Q · filed 2022-08-04 | 9.41M shares 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | 8.89M shares 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | 7.78M shares 10-K · filed 2023-02-23 | ||||||
| 2020-09-30 | 7.64M shares 10-Q · filed 2021-11-10 | 7.64M shares 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | 67.94M shares 10-Q · filed 2021-08-12 | 67.65M shares 10-Q · filed 2020-08-27 | 67.94M shares 10-Q · filed 2021-08-12 | 67.65M shares 10-Q · filed 2020-08-27 | |||
| 2020-03-31 | 67.73M shares 10-Q · filed 2021-05-13 | ||||||
| 2019-12-31 | 65.87M shares 10-K · filed 2022-02-24 | ||||||
| 2019-09-30 | 65.77M shares 10-Q · filed 2020-11-12 | 65.77M shares 10-Q · filed 2020-11-12 | |||||
| 2019-06-30 | 65.59M shares 10-Q · filed 2020-08-27 | 65.59M shares 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |